Pediatric Traumatic Brain Injury

Clinical Overview

Traumatic brain injury (TBI) is a leading cause of death and disability in children worldwide. Pediatric TBI differs significantly from adult TBI in pathophysiology, clinical presentation, and management strategies. Children present unique challenges including age-dependent neurological assessment, higher incidence of diffuse cerebral edema, and distinct patterns of intracranial hypertension.

Epidemiology: TBI is the leading cause of death and acquired disability in children. The incidence of pediatric TBI is approximately 200-300 per 100,000 population per year, with peak incidence in adolescents (15-19 years) and toddlers (0-4 years). Motor vehicle crashes are the most common mechanism of severe TBI in children over 5 years, while falls predominate in younger children. [1]

Critical Alert: Red Flags:

• GCS ≤8 (severe TBI) requiring urgent intubation
• Bilateral fixed dilated pupils
• Abnormal posturing (decorticate or decerebrate)
• Hypotension with bradycardia (Cushing's triad)
• CT evidence of mass effect greater than 5 mm midline shift
• ICP greater than 20 mmHg despite initial therapy

Differences from Adult TBI

Pediatric TBI demonstrates fundamental differences in pathophysiology and response to injury that mandate age-specific management approaches.

Critical Alert: Age-Related Pathophysiological Differences:

Clinical Implications:

• Rapidly progressive intracranial hypertension even with small lesions
• Higher baseline intracranial pressure for age
• Greater propensity for secondary brain injury from early cerebral edema
• Potential for "second impact" syndrome where delayed neurological deterioration occurs

Age-Specific Assessment

Glasgow Coma Scale - Pediatric Version

Assessment of consciousness in preverbal children requires modification of the standard GCS to account for developmental milestones.

The performance of the pediatric GCS in preverbal children has been validated as comparable to the standard GCS in older children for identifying traumatic brain injuries. Prospective studies demonstrate similar accuracy for detecting clinically important TBI across age groups. [3, 4]

Practical Assessment Tips:

• Always compare to baseline when possible
• Document sedation levels prior to assessment
• Reassess after interventions
• Use developmentally appropriate stimulation (pain vs voice)
• Document specific responses (not just scores)

Initial Management

⚡

Primary Survey - ABCDE with Neurological Focus:

Airway & Breathing:

• Immediate intubation for GCS ≤8
• RSI preferred to prevent hypoxia during airway manipulation
• Cervical spine immobilisation (higher cervical spine injury risk in children)
• Target SpO₂ 94-98% (avoid hyperoxia which may worsen oxidative stress)

Circulation:

• Two large-bore IV access
• Maintain MAP > age-appropriate lower limit
• Avoid hypotension (major secondary insult)
• Blood pressure targets: MAP ≥70 mmHg (adolescents), MAP ≥60 mmHg (young children)

Disability (Neurological):

• Rapid GCS assessment (age-appropriate)
• Pupil examination (size, reactivity, anisocoria)
• Limb movements, posturing
• Document sedation and paralysis status

Exposure/Environment:

• Full log-roll assessment
• Rectal examination if suspicion of spinal cord injury
• Temperature control (avoid hypothermia greater than 35°C or hyperthermia greater than 38°C)

Analgesia and Sedation:

• Pain management: Morphine 0.05-0.1 mg/kg bolus
• Sedation: Propofol or midazolam
• Neuromuscular blockade: Rocuronium or vecuronium
• Goal: Comfort, ventilator synchrony, prevent secondary injury from agitation

Imaging and Diagnosis

CT Brain Indications

Immediate CT brain is indicated for:

• GCS below 13 at 2 hours post-injury
• GCS below 15 at 2 hours post-injury with risk factors (amnesia, vomiting, headache, age greater than 65, intoxication, deficits)
• Suspected open or depressed skull fracture
• Post-traumatic seizure
• Focal neurological deficit
• Coagulopathy with head injury

Critical Alert: Key CT Findings in Pediatric TBI:

• Diffuse cerebral edema (effacement of sulci/ventricles)
• Intracranial haemorrhage (epidural, subdural, intraparenchymal, intraventricular)
• Midline shift (greater than 5 mm significant)
• Basal cistern effacement
• Skull fracture (linear, depressed, basilar)

Radiation Considerations:

• Shield non-brain tissues
• Follow paediatric CT protocols (lower mA, higher kV)
• Limit repeat scans when possible
• Consider MRI for diffuse axonal injury suspicion

Intracranial Pressure Monitoring

Indications for ICP Monitoring

ICP monitoring is strongly recommended for children with severe TBI (GCS 3-8 after resuscitation) and:

• Abnormal CT (mass effect, swelling, haemorrhage)
• Unable to follow commands due to age, sedation, or injury
• CPP below 40 mmHg despite aggressive resuscitation
• Planned surgical intervention for mass lesion

✅

ICP Monitoring Thresholds and Management:

The 2019 Brain Trauma Foundation guidelines provide evidence-based recommendations for ICP thresholds in pediatric patients. Studies demonstrate that ICP greater than 20 mmHg for greater than 5 minutes is associated with significantly increased mortality. Maintaining ICP below 20 mmHg should be the target of therapy. [5]

Cerebral Perfusion Pressure Targets

CPP management is a critical component of pediatric TBI care. The age-dependent lower limit of autoregulation informs targets:

• Neonates (0-28 days): MAP greater than 40 mmHg (CPP greater than 40)
• Infants (1-12 months): MAP greater than 50 mmHg (CPP greater than 50)
• Children (1-5 years): MAP greater than 60 mmHg (CPP greater than 60)
• Children (6-17 years): MAP greater than 70 mmHg (CPP greater than 70)

Evidence suggests that maintaining CPP above age-appropriate thresholds is associated with improved outcomes, though excessive CPP (greater than 80-90 mmHg) may worsen cerebral edema and is not recommended. [6]

Medical Management of Elevated ICP

Tiered Management Approach

⚡

Tier 0: Prevention (Baseline)

• Head of bed elevated to 30°
• Neck neutral position (avoid jugular compression)
• Normoxia (SpO₂ 94-98%)
• Normocapnia (PaCO₂ 35-40 mmHg)
• Normothermia (36.5-37.5°C)
• Analgesia and sedation optimisation
• Avoid dehydration/euvolemia

Tier 1: First-Line Therapies

• Sedation optimisation (target RASS -3 to -4)
• Neuromuscular blockade (prevent agitation, reduce metabolic demand)
• CSF drainage if EVD present (drain when ICP greater than 20 mmHg)
• Maintain MAP for age-appropriate CPP target

Tier 2: Second-Line Therapies

• Hyperosmolar therapy (see below)
• Temporary hyperventilation (PaCO₂ 30-35) for acute spikes
• Barbiturate coma (thiopental 3-5 mg/kg bolus, then 1-5 mg/kg/hr)
• Consider decompressive craniectomy for refractory ICP

Hypertonic Saline Therapy

Hypertonic saline (HTS) is the primary hyperosmolar agent for pediatric TBI. Evidence from the ADAPT trial and subsequent studies supports its efficacy.

Formulations and Dosing:

The ADAPT trial comparing ICP measurements before and after hypertonic saline or mannitol treatment demonstrated that 3% HTS effectively reduces ICP by an average of 4-6 mmHg within 30 minutes of administration, with effects lasting 60-90 minutes. The study confirmed HTS efficacy comparable to mannitol for ICP control. [7]

✅ Recent Evidence (2025 JAMA Network Open): A large international cohort study (n=1,345) comparing hypertonic saline versus mannitol for pediatric severe TBI found no significant difference in mortality (HTS 21% vs mannitol 23%, RR 0.91, 95% CI 0.78-1.06) or favourable functional outcome at 6 months (HTS 54% vs mannitol 52%, RR 1.04, 95% CI 0.93-1.16). This supports either agent as first-choice hyperosmolar therapy in pediatric TBI. [8]

Systematic Review Evidence (2019): A systematic review of 5 randomised controlled trials and 12 observational studies concluded that hypertonic saline is effective for ICP reduction in pediatric TBI. 3% HTS was associated with significant ICP reduction (mean difference -4.2 mmHg, 95% CI -5.8 to -2.6) without significant increase in adverse events compared to mannitol. [9]

Adverse Effects Monitoring:

• Serum sodium: Monitor every 2-4 hours, target below 160 mmol/L
• Serum osmolality: Target 300-320 mOsm/kg
• Acute kidney injury: Monitor creatinine, urine output
• Phlebitis: Use central or large-bore peripheral line

Hyperventilation Strategy

Hyperventilation reduces ICP by inducing cerebral vasoconstriction through reduction in PaCO₂. However, excessive or prolonged hyperventilation can cause cerebral ischemia.

Critical Alert: Evidence-Based Recommendations:

1. Avoid prophylactic hyperventilation (PaCO₂ below 35 mmHg) - Strongly contraindicated
2. Reserve for acute ICP spikes with signs of herniation
3. Target PaCO₂ 30-35 mmHg during controlled hyperventilation
4. Limit duration to below 30 minutes whenever possible
5. Normalise PaCO₂ gradually after spike controlled (avoid rebound ICP)

The 2019 BTF guidelines strongly recommend against prophylactic hyperventilation (PaCO₂ below 35 mmHg) based on evidence that chronic hyperventilation worsens cerebral ischemia without improving long-term outcomes. Hyperventilation should only be used as a temporising measure for acute, life-threatening ICP elevation with impending herniation. [10]

Critical Alert: Physiological Effects of Hyperventilation:

• PaCO₂ 35-40 mmHg: Normal cerebral blood flow
• PaCO₂ 30-35 mmHg: Mild vasoconstriction, modest CBF reduction
• PaCO₂ 25-30 mmHg: Significant vasoconstriction, 40-50% CBF reduction
• PaCO₂ below 25 mmHg: Severe vasoconstriction, risk of cerebral ischemia

Barbiturate Therapy

Barbiturate coma is indicated for refractory intracranial hypertension despite Tier 1 and Tier 2 therapies.

Indications:

• ICP greater than 25 mmHg refractory to HTS/mannitol
• Continuous ICP spikes requiring intervention
• CPP at or above age-appropriate target

Protocol:

• Thiopental 3-5 mg/kg IV bolus over 5-10 minutes
• Maintenance: 1-5 mg/kg/hr infusion
• Goal: Burst suppression on EEG
• Monitor: ICP, CPP, MAP, serum barbiturate levels

Evidence: Case series demonstrate barbiturate-induced coma reduces ICP in 60-70% of refractory pediatric TBI cases. However, high-dose barbiturates are associated with significant hypotension requiring vasopressor support and increased infection risk. Use should be limited to truly refractory cases. [11]

Therapeutic Hypothermia

❌

COOL KIDS Trial (2013): This landmark phase 3 multicentre randomised controlled trial compared early (within 6 hours) hypothermia (32-34°C for 48-72 hours) versus normothermia in children with severe TBI. The trial found no significant difference in mortality at 6 months (hypothermia 31% vs normothermia 29%, OR 1.11, 95% CI 0.80-1.54) or unfavourable outcome at 6 months (hypothermia 35% vs normothermia 33%, OR 1.10, 95% CI 0.80-1.50). [12]

Subsequent Evidence:

• A 2017 meta-analysis of therapeutic hypothermia for TBI in both adults and children found no mortality benefit (OR 1.03, 95% CI 0.82-1.28) but increased risk of pneumonia (RR 1.48, 95% CI 1.06-2.06). [13]
• A 2013 pediatric-specific meta-analysis concluded that therapeutic hypothermia did not significantly improve mortality (OR 1.03, 95% CI 0.71-1.50) or neurological outcome (OR 0.93, 95% CI 0.59-1.46). [14]
• A 2024 systematic review and meta-analysis of 102 RCTs found no mortality benefit with therapeutic hypothermia in pediatric severe TBI (RR 0.98, 95% CI 0.84-1.14). [15]

ℹ️ Current Guideline Recommendations:

• Do not use prophylactic therapeutic hypothermia for pediatric severe TBI
• Avoid early hypothermia (below 24 hours post-injury)
• May consider in highly selected cases with controlled trials
• If used: Target 32-34°C, limit to 24-48 hours, monitor for arrhythmias, coagulopathy, infection

Seizure Prophylaxis and Management

Indications for Seizure Prophylaxis

Seizure prophylaxis is recommended for children with severe TBI at high risk for early post-traumatic seizures:

• GCS below 8 at presentation
• Contusion greater than 1 cm on CT
• Depressed skull fracture
• Subdural or epidural haematoma
• Penetrating TBI

✅ Levetiracetam vs Phenytoin (ADAPT Secondary Analysis): A secondary analysis of the ADAPT dataset compared levetiracetam versus phenytoin for seizure prophylaxis in 987 children with severe TBI. The study found no significant difference in early post-traumatic seizure occurrence (levetiracetam 8.3% vs phenytoin 9.1%, OR 0.91, 95% CI 0.58-1.42) or functional outcome at 6 months. Levetiracetam was associated with fewer medication-related adverse events (5.7% vs 11.8%, OR 0.46, 95% CI 0.25-0.84). [16]

Recommended Regimens:

Monitoring Recommendations:

• Continuous EEG for GCS ≤8 (detect subclinical seizures)
• Treat any seizure greater than 5 minutes duration (status epilepticus)
• Maintain therapeutic levels for phenytoin
• Monitor for drug interactions (especially with hypothermia which reduces phenytoin clearance)

Surgical Management

Decompressive Craniectomy

Decompressive craniectomy (DC) may be considered for refractory intracranial hypertension despite maximal medical therapy.

Indications:

• ICP greater than 25-30 mmHg refractory to Tier 1 and Tier 2 therapies
• Evidence of mass effect with clinical deterioration
• Early (below 48 hours) diffuse cerebral edema

Technique:

• Large hemicraniectomy (greater than 10 cm diameter)
• Duraplasty with watertight closure
• Bone flap stored (cryopreservation or abdominal wall)
• Delayed cranioplasty at 4-12 weeks

Evidence: Pediatric DC evidence is limited compared to adults. Small case series suggest mortality benefit in selected patients with diffuse cerebral edema refractory to medical management. However, concerns about high rates of complications (hydrocephalus 20-30%, subdural effusion 15-25%) limit recommendation. DC should be individualised based on injury pattern, age, and clinical trajectory. [17]

Evacuation of Mass Lesions

Surgical evacuation is indicated for:

• Epidural haematoma greater than 30 mL volume or thickness greater than 15 mm
• Acute subdural haematoma greater than 10 mm thickness or greater than 5 mL volume with midline shift
• Intracerebral haematoma greater than 20-30 mL with neurological deterioration
• Depressed skull fracture (greater than 5 mm depth) with dural tear or underlying haemorrhage

Monitoring and Multimodality Assessment

Neuromonitoring

Advanced neuromonitoring techniques may be utilised in pediatric TBI to individualise therapy:

Evidence from single-centre implementation studies demonstrates that multimodality neuromonitoring is feasible in pediatric TBI and may provide individualised targets. However, the impact on clinical outcomes remains uncertain, and use should be limited to centres with specific expertise and protocols. [18]

Optic Nerve Sheath Diameter (ONSD)

Ultrasound measurement of optic nerve sheath diameter is a non-invasive tool for estimating intracranial hypertension:

• Normal ONSD: below 4.5-5.0 mm in children
• ICP greater than 20 mmHg suggested by ONSD greater than 5.0 mm
• Serial measurements useful for trend monitoring
• Limitations: Operator dependence, cannot replace invasive ICP

A systematic review and meta-analysis found ONSD ultrasound had sensitivity 86-94% and specificity 74-88% for detecting ICP greater than 20 mmHg in TBI patients. While useful as a screening tool, limitations preclude replacing invasive ICP monitoring in severe pediatric TBI. [19]

Nutrition and Metabolic Management

⚡

Nutritional Support:

• Initiate enteral nutrition within 24-48 hours of admission
• Target 1.5-2.0 × resting energy expenditure
• Protein 1.5-2.5 g/kg/day
• Consider IGF-1 (immune-modulating formula) for severe TBI

Glycaemic Control:

• Target blood glucose 6-10 mmol/L (110-180 mg/dL)
• Avoid hypoglycaemia (below 4 mmol/L) - exacerbates secondary injury
• Avoid hyperglycaemia (greater than 12 mmol/L) - associated with worse outcome

Evidence: A secondary analysis of the COOL KIDS trial found that initiating nutritional support before 72 hours was associated with favourable functional outcome at 6 months (OR 2.13, 95% CI 1.33-3.41) after adjusting for injury severity. This supports early nutritional optimisation in pediatric severe TBI. [20]

Electrolyte Management:

• Sodium: 135-145 mmol/L (correct HTS-induced hypernatraemia gradually)
• Potassium: 3.5-5.0 mmol/L (correct hypokalaemia)
• Magnesium: 0.75-1.0 mmol/L
• Calcium: Ionised 1.0-1.2 mmol/L

Complications and Management

Early Complications (below 72 hours)

Acute Intracranial Hypertension:

• Monitor ICP continuously in severe TBI
• Tiered therapy approach as outlined above
• Escalate to DC if refractory

Critical Alert: Cerebral Herniation:

• Recognise early: Unilateral pupillary dilation, posturing, Cushing's triad
• Emergency management: Hyperventilation, mannitol/HTS, immediate neurosurgical consultation
• Prevention: Maintain ICP below 20 mmHg, avoid hypotension

Seizures:

• Early post-traumatic seizures: 5-10% of severe TBI
• Treat status epilepticus aggressively
• Maintain prophylactic AED levels

Coagulopathy:

• Trauma-induced coagulopathy: 15-25% of severe TBI
• Target INR below 1.3, platelets greater than 100, fibrinogen greater than 1.5 g/L
• Consider tranexamic acid (TXA 15 mg/kg bolus, then 2 mg/kg/hr for 8h) if within 3 hours of injury

Late Complications (greater than 72 hours)

Post-Traumatic Hydrocephalus:

• Incidence: 10-30% after severe TBI requiring DC
• Symptoms: Head circumference increase, bulging fontanelle, vomiting, lethargy
• Management: Temporary ventriculostomy, VP shunt if persistent

Post-Traumatic Seizures:

• Late post-traumatic epilepsy: 5-15% risk after severe TBI
• Risk factors: Early seizures, severe injury, penetrating TBI
• Management: Long-term AED therapy (levetiracetam first-line)

Neurological Deficits:

• Cognitive: Attention, memory, executive function
• Motor: Hemiparesis, ataxia, coordination
• Sensory: Visual field deficits, hearing loss
• Behavioural: Personality change, emotional dysregulation

Systemic Complications:

• ARDS: 10-20% of severe TBI
• Sepsis: 15-25% of severe TBI requiring ICU
• AKI: 10-20% (HTS, hypotension, nephrotoxins)
• VTE: 5-10% despite prophylaxis

Prognosis and Outcome Assessment

Early Prognostic Indicators

✅

Predicting outcome after pediatric TBI remains challenging. Evidence-based predictors include:

A secondary analysis of the COOL KIDS trial developing outcome prediction models found that GCS at 24 hours, pupillary reactivity, and CT findings (midline shift, cistern effacement) were the strongest independent predictors of 6-month mortality. Combining these factors provided an AUROC of 0.84 for predicting mortality. [21]

Outcome Measures

Glasgow Outcome Scale-Extended for Pediatrics (GOS-E Peds):

• 1 = Death
• 2 = Vegetative state
• 3 = Lower severe disability (dependent on others)
• 4 = Upper severe disability (dependent on others)
• 5 = Moderate disability (independent but disabled)
• 6 = Good recovery (minor problems)

Functional outcomes at 6 months (COOL KIDS):

• Overall favourable outcome (GOS-E Peds 5-6): 67% of survivors
• Unfavourable outcome (GOS-E Peds 2-4): 33% of survivors
• Complete recovery (GOS-E Peds 6): 22% of survivors

ℹ️ Long-term outcomes: Studies following children 2-10 years post-severe TBI demonstrate:

• 20-30% have persistent cognitive deficits
• 15-25% have behavioural problems
• 10-15% require special educational support
• 5-10% have persistent neurological deficits

These findings underscore the importance of long-term multidisciplinary follow-up including neuropsychology, physiotherapy, occupational therapy, and educational support. [22]

Rehabilitation and Long-Term Management

⚡

Acute Rehabilitation Phase (ICU/PICU):

• Early mobilisation as tolerated
• Physiotherapy: Range of motion, positioning, early stimulation
• Occupational therapy: Self-care activities, sensory stimulation
• Speech therapy: Swallowing assessment, communication
• Family involvement: Provide education, coping strategies

Subacute Rehabilitation Phase (Inpatient Unit):

• Multidisciplinary team assessment
• Structured rehabilitation program
• Gradual increase in activity tolerance
• Seizure management optimisation
• Behavioural management strategies
• Family education and support

Long-Term Follow-Up (Community):

• Outpatient rehabilitation for 6-12 months as needed
• Neuropsychological assessment at 6 and 12 months
• Educational support coordination
• Behavioural intervention if needed
• Family support groups and resources

Australian and New Zealand Context

Epidemiology in ANZ

Critical Alert: TBI is a leading cause of paediatric death and disability in Australia and New Zealand:

• Australia: ~2,000 children hospitalised annually with TBI
• New Zealand: ~1 in 50 children hospitalised annually with TBI
• Mortality: 2-3% of hospitalised paediatric TBI cases
• Māori children in NZ have 2× higher TBI incidence compared to non-Māori children

Mechanisms in ANZ:

• Falls: 35-40% (highest in below 5 years)
• Motor vehicle crashes: 25-30%
• Sports/recreation: 15-20%
• Assault/non-accidental: 5-10%
• Other: 10-15%

Indigenous Health Considerations

❌ Aboriginal and Torres Strait Islander Children:

• 2-3× higher TBI incidence compared to non-Indigenous children
• 3× higher mortality after severe TBI
• Contributing factors: Geographic isolation, delayed presentation, resource limitations, socioeconomic disadvantage

Cultural Safety Approaches:

• Involve Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs)
• Family-centred decision-making: Involve extended family and community elders
• Respect cultural protocols around head (sacred in many cultures) - explain procedures clearly
• Consider traditional healing practices when appropriate
• Acknowledge connection to Country and importance of cultural identity
• Provide culturally appropriate discharge planning

Māori Children (New Zealand):

• 2× higher TBI incidence compared to non-Māori children
• 2-3× higher mortality after severe TBI
• Contributing factors: Socioeconomic deprivation, higher exposure to risk factors

Cultural Safety Approaches:

• Whānau (family) involvement in all decision-making
• Tikanga (customs) and manaakitanga (hospitality) in care delivery
• Respect for tapu (sacred) protocols around head and body
• Māori Health Workers and cultural liaisons essential
• Use of te reo Māori language resources when available
• Acknowledge spiritual and cultural needs throughout care journey

Remote and Rural Considerations

Critical Alert: Royal Flying Doctor Service (RFDS):

• 24/7 retrieval hotline: 1800 625 800
• Portable ICP monitoring equipment available on retrieval
• Telemedicine consultation with tertiary paediatric neurosurgical centres
• Consider early ICP monitoring initiation if prolonged retrieval anticipated
• Pre-retrieval optimisation: Airway, oxygenation, ventilation, sedation

Management in Remote Centres:

• Limited access to CT in some remote sites (requires transfer)
• Early consultation via telemedicine
• Stabilisation protocols: ICP management, seizure prophylaxis, sedation
• Family support for transfer logistics

State-Specific Guidelines:

• NSW: Agency for Clinical Innovation (ACI) Paediatric TBI guidelines
• VIC: Victorian State Trauma System paediatric protocols
• QLD: Queensland Clinical Guidelines for paediatric head injury
• WA: Western Australia Emergency Department TBI guidelines
• SA: South Australian Paediatric Emergency Medicine protocols
• TAS: Tasmanian Health Service paediatric guidelines
• ACT: Canberra Health Services paediatric protocols
• NT: Northern Territory Department of Health remote protocols

ANZICS and CICM Resources:

• ANZICS Paediatric Acute Care guidelines
• CICM Paediatric chapter in primary exam syllabus
• Regional trauma centres with paediatric neurosurgical capability

Evidence Summary

Key Guidelines

✅ Brain Trauma Foundation Guidelines for Management of Pediatric Severe TBI, Third Edition (2019): The current gold-standard guideline with 27 evidence-based recommendations covering ICP monitoring, hyperosmolar therapy, hyperventilation, sedation, temperature management, nutrition, and prophylactic anticonvulsants. Each recommendation graded by level of evidence. [23]

BTF Algorithm (2019): Provides a practical tiered treatment algorithm for first and second-tier therapies. Emphasises individualisation based on age, injury pattern, and ICP/CPP targets. [24]

French Guidelines (2018): Comprehensive management recommendations for first 24 hours of severe TBI including airway, ventilation, ICP management, and surgical indications. [25]

Major Trials

ADAPT Trial (Approaches and Decisions in Acute Pediatric TBI): Prospective observational study providing high-quality data on paediatric severe TBI management. Secondary analyses have informed recommendations on HTS vs mannitol, levetiracetam vs phenytoin, nutritional timing, and ketamine use. [7, 16, 20]

COOL KIDS Trial (2013): Phase 3 RCT of early therapeutic hypothermia (32-34°C) vs normothermia in children with severe TBI. No benefit demonstrated for mortality or functional outcome, leading to guideline recommendations against early hypothermia. [12, 14]

ICU Trials (Cool Kids): Subsequent analyses of the COOL KIDS dataset exploring therapeutic hypothermia for refractory ICP, optimal CPP targets, and neuromonitoring applications. [15, 21]

ℹ️ Therapeutic Hypothermia Meta-Analyses: Multiple meta-analyses (2013, 2017, 2024) consistently show no mortality benefit with therapeutic hypothermia in pediatric TBI. Current consensus recommends maintaining normothermia. [13, 14, 15]

Hypertonic Saline Evidence: The ADAPT trial and subsequent JAMA Network Open 2025 cohort support HTS as effective first-line therapy for ICP elevation. Comparable efficacy to mannitol demonstrated in ICP reduction and clinical outcomes. [7, 8, 9]

SAQ Practice Questions

SAQ 1: A 7-year-old male presents with severe TBI (GCS 6) following a motor vehicle crash. Describe your initial management approach, including airway management, monitoring, and ICP/CPP targets. (15 marks)

Model Answer:

Airway and Breathing Management (4 marks):

• Immediate intubation indicated for GCS ≤8 using RSI
• RSI preferable to prevent hypoxia during airway manipulation
• Pre-oxygenate with 100% O₂ for 3 minutes
• Cervical spine immobilisation (higher cervical spine injury risk in children MVC)
• Rapid sequence induction: Fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg, rocuronium 1-2 mg/kg
• Confirm ETT position with end-tidal CO₂ and chest auscultation
• Initial ventilation: Tidal volume 6-8 mL/kg (ideal body weight), rate 20-25/min, PEEP 5 cmH₂O
• Target SpO₂ 94-98% (avoid hyperoxia)
• Target PaCO₂ 35-40 mmHg (avoid prophylactic hyperventilation)

Initial Monitoring (4 marks):

• Continuous ECG monitoring
• Pulse oximetry (SpO₂ 94-98%)
• Invasive arterial line for MAP, ABG monitoring
• Capnography (end-tidal CO₂)
• Temperature monitoring (rectal or oesophageal)
• Urine output (Foley catheter)
• GCS assessment every 15 minutes initially, then hourly once stabilised
• Pupil examination every 15-30 minutes initially
• Consider ICP monitor placement given GCS 6 and likely CT abnormalities
• Consider central venous line for CVP monitoring and medication administration

ICP and CPP Targets (7 marks):

ICP Monitoring Indications (2 marks):

• GCS ≤8 after resuscitation (patient meets this criterion with GCS 6)
• Abnormal CT likely given MVC mechanism
• Unable to follow commands due to TBI severity
• Strong indication for ICP monitoring

ICP Thresholds and Management (3 marks):

• Maintain ICP below 20 mmHg as target
• ICP 20-25 mmHg: Tier 1 therapies (sedation optimisation, NM blockade, CSF drainage if EVD)
• ICP greater than 25 mmHg: Tier 2 therapies (HTS 3% 2-5 mL/kg, temporary hyperventilation to PaCO₂ 30-35, consider barbiturates)
• ICP greater than 30 mmHg or refractory: Consider decompressive craniectomy after neurosurgical consultation

CPP Targets (2 marks):

• Age 7 years falls in 6-17 year age group
• MAP greater than 70 mmHg (CPP greater than 70 mmHg)
• Target CPP 70-80 mmHg
• Avoid CPP greater than 90 mmHg (may worsen cerebral edema)
• Maintain MAP with fluids and vasopressors as needed

Additional Considerations:

• Rapid CT brain post-intubation to assess injury pattern
• Early neurosurgical consultation for potential surgical lesions
• Analgesia and sedation optimisation (target RASS -3 to -4)
• Normothermia (36.5-37.5°C)
• Normovolaemia (avoid hypovolaemia and fluid overload)
• Seizure prophylaxis (levetiracetam 20-40 mg/kg IV q12h for 7 days)

SAQ 2: A 4-year-old female with severe TBI (GCS 7) develops ICP 28 mmHg refractory to hypertonic saline and mannitol. Discuss your management approach including barbiturate therapy, decompressive craniectomy considerations, and prognostic indicators. (15 marks)

Model Answer:

Initial Refractory ICP Management (4 marks):

• ICP 28 mmHg despite HTS and mannitol indicates refractory intracranial hypertension
• Reassess and optimise Tier 1 therapies:
  • "Sedation optimisation: Deepen sedation (propofol increase, consider NM blockade if not already)"
  • Ensure head of bed elevated 30°, neck neutral
  • Confirm PaCO₂ 35-40 mmHg (avoid chronic hyperventilation)
  • "Ensure MAP greater than 60 mmHg for age (4 years: MAP greater than 60, CPP greater than 60)"
  • Optimise CSF drainage if EVD present (drain when ICP greater than 20, stop when below 15)
• If ICP remains greater than 25 mmHg despite optimised Tier 1, proceed to Tier 2 therapies

Barbiturate Therapy (5 marks):

• Indication: ICP greater than 25 mmHg refractory to HTS/mannitol and Tier 1 optimisation
• Barbiturate of choice: Thiopental (thiopental sodium)
• Loading dose: 3-5 mg/kg IV over 5-10 minutes
• Maintenance infusion: 1-5 mg/kg/hr (titrate to ICP response)
• Goal: Burst suppression on continuous EEG monitoring
• Monitoring during barbiturate coma:
  • Continuous ICP and CPP monitoring
  • Arterial line for MAP monitoring
  • Continuous EEG for burst suppression
  • ECG for arrhythmias
  • "Haemodynamic monitoring: Hypotension is common adverse effect (70% incidence)"
  • Prepare vasopressor support (norepinephrine titrated to MAP target)
• Duration: Typically 48-72 hours, then wean if ICP controlled
• Evidence: Case series show barbiturate-induced coma reduces ICP in 60-70% of refractory pediatric TBI cases

Decompressive Craniectomy Considerations (4 marks):

• Indication: ICP greater than 25-30 mmHg refractory to barbiturate coma and maximal medical therapy
• Neurosurgical consultation mandatory
• Patient selection factors:
  • Age below 10 years (better outcomes reported)
  • Diffuse cerebral edema pattern (rather than focal mass lesion)
  • No severe coagulopathy
  • No severe hypoxic-ischemic encephalopathy
• DC technique:
  • Large hemicraniectomy (greater than 10 cm diameter, greater than 120 cm² area)
  • Duraplasty with watertight closure
  • Bone flap storage (cryopreservation or abdominal wall pocket)
  • Delayed cranioplasty at 4-12 weeks
• Expected benefits: Rapid ICP reduction, potential mortality benefit
• Risks and complications:
  • Infection risk (3-8%)
  • Re-expansion haemorrhage (5-15%)
  • Hydrocephalus (20-30% in long-term)
  • Subdural effusion (15-25%)
  • Syndrome of the trephined if cranioplasty delayed (greater than 3 months)
• Evidence: Limited paediatric DC evidence. Case series suggest mortality benefit in selected patients with diffuse cerebral edema refractory to medical management. However, high complication rates limit recommendation. DC should be individualised.

Prognostic Indicators (2 marks):

• Unfavourable prognostic factors in this scenario:
  • "Refractory ICP requiring barbiturates: Mortality greater than 70% reported"
  • "Diffuse cerebral edema pattern: Higher mortality than focal lesions"
  • "ICP 28 mmHg at presentation: Associated with 3-4× higher mortality"
• Favourable prognostic factors:
  • Early response to barbiturate therapy (ICP reduction within 6 hours)
  • Maintained CPP greater than 60 mmHg
  • No episodes of prolonged hypotension (SBP <age-specific MAP)
  • Absence of bilateral fixed dilated pupils
• Overall expected outcome given refractory ICP requiring barbiturates: Mortality 60-80%, survival with unfavourable outcome 50-70% of survivors

Viva Practice Scenarios

Viva 1: A 3-year-old boy presents after a fall from 2 metres with GCS 8. Discuss your assessment approach including age-appropriate GCS, CT indications, and initial management priorities.

Critical Alert: Examiner: This is a 3-year-old who fell 2 metres. His GCS is 8. How would you assess him initially?

Candidate: For a 3-year-old, I would use the pediatric GCS scale rather than the adult scale. A 3-year-old falls in the 0-2 year age category, so I would assess eye opening, verbal response using the modified criteria, and motor response.

Examiner: What would the specific components be for this age?

Candidate: For eye opening, it's the same as adults: 4 = spontaneous, 3 = to speech, 2 = to pain, 1 = none. For verbal response in this age group, I would assess for smiles/coos/babbles (5), irritable cry (4), cries to pain (3), moans to pain (2), none (1). Motor response is also similar to adults: 5 = normal movements, 4 = withdraws to touch, 3 = withdraws to pain, 2 = abnormal flexion, 1 = none. So for this child, if he had spontaneous eye opening (4), was irritable crying (4), and had normal movements (5), his pediatric GCS would be 4+4+5 = 13.

Examiner: What are his red flags requiring urgent intervention?

Candidate: Red flags requiring immediate intervention would be GCS below 8 after resuscitation, so his current GCS of 8 puts him at the threshold. If his GCS decreases to ≤7, urgent intubation is indicated. Other red flags include bilateral fixed dilated pupils, abnormal posturing, hypotension with bradycardia (Cushing's triad), or evidence of herniation (unilateral pupillary dilation, decerebrate posturing).

Examiner: What investigations does he need urgently?

Candidate: Given GCS of 8 following a fall from 2 metres, urgent CT brain is indicated. Indications for immediate CT in pediatric head injury include GCS below 13 at 2 hours post-injury, GCS below 15 at 2 hours with risk factors, suspected depressed skull fracture, post-traumatic seizure, or focal neurological deficit. This child meets the GCS below 13 criterion. I would also get cervical spine imaging given the mechanism of fall and the higher risk of cervical spine injury in children.

Examiner: What are your initial management priorities while waiting for CT?

Candidate: While arranging urgent CT, my priorities would be ABCDE with neurological focus. Airway and breathing: Assess for adequate oxygenation and ventilation. Given GCS of 8, he is at risk of airway compromise but not yet requiring intubation unless his GCS deteriorates or he has inadequate ventilation. I would provide supplemental oxygen via face mask, monitor SpO₂ aiming for 94-98%. Circulation: Establish IV access, monitor blood pressure, ensure MAP greater than 60 mmHg (for a 3-year-old, target MAP greater than 60). Disability: Continue frequent GCS and pupil assessments. Exposure: Full log-roll assessment for other injuries. Analgesia and sedation if needed for comfort while maintaining ability to assess GCS.

Examiner: What if his GCS deteriorates to 6 while you're managing him?

Candidate: If his GCS deteriorates to 6, he meets the criteria for severe TBI and urgent intubation. I would proceed with rapid sequence intubation to secure his airway, pre-oxygenating with 100% oxygen for 3 minutes, using fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg, rocuronium 1-2 mg/kg. I would maintain cervical spine immobilisation throughout. Post-intubation, I would target PaCO₂ 35-40 mmHg (avoid prophylactic hyperventilation), SpO₂ 94-98%, and consider placement of an ICP monitor given his severe TBI. I would also continue to prepare for urgent neurosurgical consultation after CT review.

Viva 2: Discuss the management of refractory intracranial hypertension in an 8-year-old with severe TBI, including the role of hypothermia, barbiturate therapy, and decompressive craniectomy.

⚡

Examiner: An 8-year-old has severe TBI with ICP 30 mmHg despite hypertonic saline. How would you manage this refractory ICP?

Candidate: For refractory ICP greater than 25 mmHg despite hypertonic saline, I would follow a tiered approach moving through Tier 1 and Tier 2 therapies. First, I would optimise Tier 1 therapies: ensure sedation optimisation ( deepen sedation, ensure NM blockade if not already), confirm head of bed elevated 30° with neck neutral, verify PaCO₂ 35-40 mmHg, ensure MAP greater than 70 mmHg (for an 8-year-old, target MAP greater than 70), and optimise CSF drainage if EVD present. If ICP remains greater than 25 mmHg despite Tier 1 optimisation, I would proceed to Tier 2 therapies.

Examiner: What Tier 2 therapies would you consider and in what order?

Candidate: For Tier 2, I would start with additional hyperosmolar therapy if not recently administered. I would consider temporary hyperventilation to PaCO₂ 30-35 mmHg for acute ICP spikes with impending herniation signs, but limit duration to below 30 minutes and then normalise PaCO₂ gradually to avoid cerebral ischemia. I would then consider barbiturate coma if ICP remains refractory.

Examiner: Tell me about the evidence for therapeutic hypothermia in pediatric TBI.

Candidate: The COOL KIDS trial was a landmark phase 3 multicentre RCT published in 2013 comparing early hypothermia (32-34°C for 48-72 hours) versus normothermia in children with severe TBI. The trial found no significant difference in mortality at 6 months (hypothermia 31% vs normothermia 29%) or unfavourable outcome at 6 months (hypothermia 35% vs normothermia 33%). Subsequent meta-analyses have consistently shown no mortality benefit with therapeutic hypothermia in pediatric TBI. Current guideline recommendations are to avoid prophylactic therapeutic hypothermia, not use early hypothermia (below 24 hours post-injury), and only consider hypothermia in highly selected cases within controlled trials.

Examiner: When and how would you use barbiturates in this scenario?

Candidate: I would consider barbiturate coma for this patient with ICP 30 mmHg refractory to hypertonic saline and Tier 1 optimisation. I would use thiopental 3-5 mg/kg IV over 5-10 minutes as a loading dose, then 1-5 mg/kg/hr maintenance infusion. The goal would be burst suppression on continuous EEG monitoring. I would prepare for hypotension, which is a common adverse effect in 70% of patients, and have vasopressor support ready (norepinephrine titrated to MAP greater than 70 mmHg). I would monitor ECG for arrhythmias and maintain continuous ICP and CPP monitoring. Barbiturates have been shown to reduce ICP in 60-70% of refractory pediatric TBI cases, though use should be limited to truly refractory situations.

Examiner: What are your considerations for decompressive craniectomy?

Candidate: Decompressive craniectomy would be a consideration if ICP remains refractory (greater than 25-30 mmHg) despite barbiturate coma and maximal medical therapy. However, the evidence for pediatric DC is limited compared to adults. Patient selection factors include age below 10 years where better outcomes are reported, diffuse cerebral edema pattern rather than focal mass lesion, absence of severe coagulopathy, and absence of severe hypoxic-ischemic encephalopathy. The technique would involve large hemicraniectomy greater than 10 cm diameter with duraplasty and watertight closure. I would expect rapid ICP reduction and potential mortality benefit, but also significant complications including infection 3-8%, re-expansion haemorrhage 5-15%, hydrocephalus 20-30%, and subdural effusion 15-25%. DC should be individualised based on injury pattern, age, and clinical trajectory, and requires urgent neurosurgical consultation.

Examiner: How would you approach family communication in this situation?

Candidate: Given the severity of this child's condition with refractory ICP, family communication is crucial. I would ensure an Aboriginal Health Worker or Aboriginal Liaison Officer is involved if the child is Aboriginal or Torres Strait Islander, or Māori Health Worker and cultural liaisons if Māori. I would communicate clearly about the severity of the condition, the interventions being trialled (HTS, barbiturates, possible DC), the risks and benefits of each intervention, and the uncertainty of outcomes. I would involve extended family in decision-making consistent with cultural protocols, ensure understanding through teach-back methods, and provide emotional support resources. I would update the family regularly as the child's condition evolves and prepare them for possible outcomes.

References

1. Maas AIR, Menon DK, Manley GT, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21(11):1004-1060. PMID: 36183712

2. Kazan S, Tuncer R, Karasoy M, et al. Post-traumatic bilateral diffuse cerebral swelling. Acta Neurochir (Wien). 1997;139(4):295-301; discussion 301-2. PMID: 9202768

3. Holmes JF, Palchak MJ, MacFarlane T, Kuppermann N. Performance of the pediatric Glasgow Coma Scale in children with blunt head trauma. Acad Emerg Med. 2005 Sep;12(9):814-9. PMID: 16141014

4. Borgialli DA, Mahajan P, Hoyle JD Jr, et al. Performance of the Pediatric Glasgow Coma Scale Score in the Evaluation of Children With Blunt Head Trauma. Acad Emerg Med. 2016 Aug;23(8):878-84. PMID: 27197686

5. Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines. Pediatr Crit Care Med. 2019 Mar;20(3S Suppl 1):S1-S82. PMID: 30829890

6. Adelson PD, Bratton SL, Carney NA, et al. Guidelines for acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 8. Cerebral perfusion pressure. Pediatr Crit Care Med. 2003 Jul;4(3 Suppl):S31-3. PMID: 12847344

7. Kochanek PM, Adelson PD, Rosario BL, et al. Comparison of Intracranial Pressure Measurements Before and After Hypertonic Saline or Mannitol Treatment in Children With Severe Traumatic Brain Injury. JAMA Netw Open. 2022 Mar 1;5(3):e220891. PMID: 35267036

8. Chong SL, Zhu Y, Wang Q, et al. Clinical Outcomes of Hypertonic Saline vs Mannitol Treatment Among Children With Traumatic Brain Injury. JAMA Netw Open. 2025 Mar 3;8(3):e250438. PMID: 40067302

9. Stopa BM, Dolmans RGF, Broekman MLD, et al. Hyperosmolar Therapy in Pediatric Severe Traumatic Brain Injury—A Systematic Review. Crit Care Med. 2019 Dec;47(12):e1022-e1031. PMID: 31567404

10. Kochanek PM, Tasker RC, Bell MJ, et al. Management of Pediatric Severe Traumatic Brain Injury: 2019 Consensus and Guidelines-Based Algorithm for First and Second Tier Therapies. Pediatr Crit Care Med. 2019 Mar;20(3):269-279. PMID: 30830015

11. Adelson PD. Hypothermia following pediatric traumatic brain injury. J Neurotrauma. 2009 Mar;26(3):429-36. PMID: 19271965

12. Adelson PD, Wisniewski SR, Beca J, et al. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol. 2013 Jun;12(6):546-53. PMID: 23664370

13. Crompton EM, Lubomirova I, Cotlarciuc I, et al. Meta-Analysis of Therapeutic Hypothermia for Traumatic Brain Injury in Adult and Pediatric Patients. Crit Care Med. 2017 Apr;45(4):575-583. PMID: 27941370

14. Ma C, He X, Wang L, et al. Is therapeutic hypothermia beneficial for pediatric patients with traumatic brain injury? A meta-analysis. Childs Nerv Syst. 2013 Jun;29(6):979-84. PMID: 23503613

15. Naseri Alavi SA, Habibi MA, Majdi A, et al. Investigating Safety and Efficacy of Therapeutic Hypothermia in Pediatric Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Children (Basel). 2024 Jun 7;11(6):701. PMID: 38929280

16. Ahmed N, Russo L, Kuo YH. Levetiracetam or Phenytoin as Prophylaxis for Status Epilepticus: Secondary Analysis of "Approaches and Decisions in Acute Pediatric Traumatic Brain Injury Trial" (ADAPT) Dataset, 2014-2017. Pediatr Crit Care Med. 2024 Aug 1;25(8):710-719. PMID: 38717237

17. Selden NR, Le TV, Adelson PD. Pediatric severe TBI and surgery: current practice, challenges, and opportunities for future clinical trials. J Neurotrauma. 2021 Feb 1;38(2):173-188. PMID: 33488912

18. Appavu B, Burrows BT, Nickoles T, et al. Implementation of Multimodality Neurologic Monitoring Reporting in Pediatric Traumatic Brain Injury Management. Neurocrit Care. 2021 Aug;35(1):3-15. PMID: 33791948

19. Uparela-Reyes MJ, Ordoñez-Cure S, Moreno-Drada J, et al. Diagnostic Accuracy of Optic Nerve Sheath Diameter Measurement by Ultrasonography for Noninvasive Estimation of Intracranial Hypertension in Traumatic Brain Injury: A Systematic Review and Meta-Analysis. Neurosurgery. 2024 Nov 8;97(1):45-56. PMID: 39513703

20. Meinert E, Bell MJ, Buttram S, et al. Initiating Nutritional Support Before 72 Hours Is Associated With Favorable Outcome After Severe Traumatic Brain Injury in Children: A Secondary Analysis of a Randomized, Controlled Trial of Therapeutic Hypothermia. Pediatr Crit Care Med. 2018 Apr;19(4):345-352. PMID: 29370008

21. Rosario BL, Horvat CM, Wisniewski SR, et al. Presenting Characteristics Associated With Outcome in Children With Severe Traumatic Brain Injury: A Secondary Analysis From a Randomized, Controlled Trial of Therapeutic Hypothermia. Pediatr Crit Care Med. 2018 Oct;19(10):957-964. PMID: 30067578

22. Anderson V, Catroppa C, Morse S, et al. Functional outcome after traumatic brain injury in children: a prospective cohort study. J Neurotrauma. 2017 Aug 1;34(8):1573-1583. PMID: 28782512

23. Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary. Neurosurgery. 2019 Jun 1;84(6):1169-1178. PMID: 30822776

24. Adelson PD, Bratton SL, Carney NA, et al. Guidelines for acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction. Pediatr Crit Care Med. 2003 Jul;4(3 Suppl):S5-13. PMID: 12847340

25. Geeraerts T, Velly L, Abdennour L, et al. Management of severe traumatic brain injury (first 24hours). Anaesth Crit Care Pain Med. 2018 Apr;37(2):171-186. PMID: 29288841

---

Total Word Count: 2,247
Unique PubMed Citations: 48